Table 4 Univariate and Cox proportional multivariate analyses for recurrence (n = 29) and breast cancer death (n = 17) in the 79 patients validation cohort with ER positive breast cancer, treated with tamoxifen only as systemic adjuvant therapy

Tumor size (T1 vs. T2–3)

1.4

0.67

2.9

0.37

1.3

0.48

3.3

0.63

Node status (pos vs neg)

2.1

0.97

4.6

0.059

5.3

1.51

18.7

0.0092

CAPS (high vs low)

2.4

0.98

6.0

0.049

2.8

0.80

9.6

0.11

Age (<50 vs ≥50 years)

1.00

0.97

1.03

0.82

1.01

0.98

1.05

0.60

ER cont (fmol/μg DNA)

0.87

0.77

0.98

0.026

0.76

0.60

0.95

0.018

PgR cont (fmol/μg DNA)

0.93

0.84

1.03

0.16

0.85

0.71

1.01

0.061

CAPS (high vs low)

2.4

0.98

6.0

0.056

2.8

0.80

9.6

0.11

Tumor size (T1 vs T2–3)

1.4

0.61

3.2

0.43

0.90

0.30

2.7

0.85

Node status (pos vs neg)

1.7

0.72

4.0

0.22

4.7

1.24

18.0

0.024

CAPS (high vs low)

3.6

1.3

9.7

0.011

4.0

1.04

15.1

0.043

Age (<50 vs ≥50 years)

1.00

0.97

1.03

0.87

1.02

0.99

1.06

0.24

ER cont (fmol/μg DNA)

0.88

0.76

1.01

0.073

0.72

0.55

0.96

0.025

PgR cont (fmol/μg DNA)

0.96

0.87

1.07

0.48

0.92

0.77

1,11

0.40

CAPS (high vs low)

3.6

1.3

9.7

0.011

4.0

1.04

15.1

0.043